Shanghai Ark Biopharmaceutical Co., Ltd.
Quick facts
Phase 3 pipeline
- AK0529 · Oncology
AK0529 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. - AK0901 capsule
- Matching placebo of AK0529
This is a placebo control formulation with no active pharmaceutical ingredient.
Phase 2 pipeline
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: